Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis

Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Key Stats

• Today's Range: $2.66 to $2.93
• 50-Day Range: $2.70 to $4.36
• 52-Week Range: $2.66 to $18.24
• Volume: 2.30 million shs
• Average Volume: 1.31 million shs
• Market Capitalization: $194.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.78
• Consensus Rating: Hold

Zentalis Pharmaceuticals Stock Analysis - MarketRank™

Zentalis Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 785th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Zentalis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zentalis Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($3.02) to ($3.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zentalis Pharmaceuticals is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zentalis Pharmaceuticals is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zentalis Pharmaceuticals has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.77% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Zentalis Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Zentalis Pharmaceuticals has recently decreased by 11.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zentalis Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Zentalis Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.77% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Zentalis Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Zentalis Pharmaceuticals has recently decreased by 11.34%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: N/A

News Sentiment

Zentalis Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

Search Interest

Only 1 people have searched for ZNTL on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zentalis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,098.00 in company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Zentalis Pharmaceuticals is held by insiders.

ZNTL Stock Analysis - Frequently Asked Questions

How have ZNTL shares performed this year?

Zentalis Pharmaceuticals' stock was trading at $15.15 on January 1st, 2024. Since then, ZNTL stock has decreased by 82.0% and is now trading at $2.73.
View the best growth stocks for 2024 here.

How were Zentalis Pharmaceuticals' earnings last quarter?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) announced its earnings results on Friday, August, 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by $0.40.

When did Zentalis Pharmaceuticals IPO?

Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

Who are Zentalis Pharmaceuticals' major shareholders?

Top institutional investors of Zentalis Pharmaceuticals include Wealth Enhancement Advisory Services LLC (0.10%), Exchange Traded Concepts LLC (0.06%), SG Americas Securities LLC (0.04%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Matrix Capital Management Comp, Anthony Y Sun, Cam Gallagher, Melissa B Epperly, Diana Hausman, Kimberly Blackwell, David Michael Johnson, Carrie Brownstein, Jan Skvarka, Vincent Vultaggio, Kevin D Bunker, Dimitris Voliotis and Alexis Pinto.
View institutional ownership trends.

How do I buy shares of Zentalis Pharmaceuticals?

Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Zentalis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Home Depot (HD), Chevron (CVX) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 10/31/2024
• Next Earnings (Estimated): 11/04/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZNTL
• CUSIP: N/A
• CIK: 1725160
• Web: www.zentalis.com
• Phone: 212-433-3791
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.78
• High Stock Price Target: $20.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +279.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-292,190,000.00
• Net Margins: N/A
• Pretax Margin: -479.32%
• Return on Equity: -44.22%
• Return on Assets: -35.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.59
• Quick Ratio: 6.59

Sales & Book Value

• Annual Sales: $40.56 million
• Price / Sales: 4.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.18 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 71,108,000
• Free Float: 68,548,000
• Market Cap: $201.95 million
• Optionable: Optionable
• Beta: 1.70